Publications by authors named "C V Borlongan"

Stroke is a major global health issue, ranking as the second leading cause of death and the primary cause of disability worldwide. However, current therapeutic options remain limited. Nutritional supplementation as a form of primary prevention stands as a potential stroke therapeutic.

View Article and Find Full Text PDF
Article Synopsis
  • Stem cell transplantation is a potential therapy for stroke that could be applied at various times post-stroke, but challenges remain regarding the identification of effective donor stem cells and their mechanisms of action.
  • The study highlights ProtheraCytes, a type of CD34+ cells from human blood and umbilical cords, which have shown promise in a clinical trial and are found to secrete growth factors that aid in blood vessel formation.
  • Experimental results in rats demonstrate that intranasal delivery of ProtheraCytes after a stroke significantly improved recovery and reduced brain damage, with indicators suggesting the role of specific extracellular vesicles (CD63+ EVs) in promoting regeneration and reducing inflammation.
View Article and Find Full Text PDF

Extracellular vesicles (EVs) are vital for cell-to-cell communication, transferring proteins, lipids, and nucleic acids in various physiological and pathological processes. They play crucial roles in immune modulation and tissue regeneration but are also involved in pathogenic conditions like inflammation and degenerative disorders. EVs have heterogeneous populations and cargo, with numerous subpopulations currently under investigations.

View Article and Find Full Text PDF

With a foundation built upon initial work from the 1980s demonstrating graft viability in cerebral ischemia, stem cell transplantation has shown immense promise in promoting survival, enhancing neuroprotection and inducing neuroregeneration, while mitigating both histological and behavioral deficits that frequently accompany ischemic stroke. These findings have led to a number of clinical trials that have thoroughly supported a strong safety profile for stem cell therapy in patients but have generated variable efficacy. As preclinical evidence continues to expand through the investigation of new cell lines and optimization of stem cell delivery, it remains critical for translational models to adhere to the protocols established through basic scientific research.

View Article and Find Full Text PDF